Elitek, Fasturtec(rasburicase)
Elitek, Fasturtec (rasburicase) is an enzyme pharmaceutical. Rasburicase was first approved as Fasturtec on 2001-02-23. It is used to treat hyperuricemia and tumor lysis syndrome in the USA. It has been approved in Europe to treat hyperuricemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Elitek
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elitek | Biologic Licensing Application | 2023-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperuricemia | HP_0002149 | D033461 | — |
| tumor lysis syndrome | — | D015275 | E88.3 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
rasburicase, Elitek, Sanofi-Aventis U.S. LLC | |||
| 2109-07-12 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2783 | Injection, rasburicase, 0.5 mg |
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperuricemia | D033461 | HP_0002149 | — | 6 | 7 | 5 | 4 | 8 | 30 |
| Gout | D006073 | EFO_0004274 | M10 | 7 | 6 | 9 | 4 | 2 | 28 |
| Lymphoma | D008223 | — | C85.9 | 2 | 6 | 2 | 2 | 1 | 11 |
| Tumor lysis syndrome | D015275 | — | E88.3 | 1 | 3 | 1 | 5 | 2 | 11 |
| Leukemia | D007938 | — | C95 | 2 | 6 | 2 | 1 | 1 | 10 |
| Syndrome | D013577 | — | — | 2 | 4 | 1 | 3 | — | 9 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 1 | 1 | 5 | 9 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 2 | — | 1 | 4 | 7 |
| Neoplasms | D009369 | — | C80 | 1 | — | 1 | 2 | — | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 3 | 4 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | 1 | — | — | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 2 | 1 | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | — | 2 | 1 | — | — | 3 |
| B-cell lymphoma | D016393 | — | — | — | 1 | 1 | — | — | 1 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | — | — | — | 2 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | 2 | — | — | — | 2 |
| Asymptomatic diseases | D058070 | — | — | — | 1 | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | — | 1 | — | — | — | 1 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | — | 1 | — | — | — | 1 |
| B-cell leukemia | D015448 | — | — | — | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | — | 2 | 2 |
| Pregnancy-induced hypertension | D046110 | — | O13 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Eclampsia | D004461 | HP_0100601 | O15 | — | — | — | — | 1 | 1 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rasburicase |
| INN | rasburicase |
| Description | Uricase (Urate oxidase) |
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201594 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00049 |
| UNII ID | 08GY9K1EUO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,184 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elitek
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
986 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use